The incretin effect has been shown to be reduced in patients with type 2 diabetes (T2D) [1], in prediabetic states such as impaired glucose tolerance and in obese, insulin resistant subjects with NGT [2], [3]. This evidence concerns the gene INS and type 2 diabetes mellitus.